Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc MMIRF


Primary Symbol: V.MIR

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.


TSXV:MIR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by goldyhawkon Apr 07, 2022 1:03pm
173 Views
Post# 34584882

FDA SECOND ?

FDA SECOND ?While the European process is an important first step, Chan said in a jan.20, 2022 news release, MedMira management said U.S. FDA approval of the product would be preferred by current and future customers-----

ROGER TAYLOR: Halifax's MedMira focused on cracking U.S. market with COVID testing tech--Roger Taylor | Posted: Jan. 20, 2022, 4:07 p.m. | Updated: Jan. 20, 2022, 7 p.m. | 3 Min Read


-- Medmira has only 3, 4 or 5 main customers-
The Company derives approximately 96% (January 31, 2021 – 86%) of its revenue

from five (January 31, 2021 — three) main customers and, for these customers,

assesses the recoverability of each account on a regular basis. During the three

months ended January 31, 2021, customer 1 accounted for 69% of the Company’s

revenue, customer 2 accounted for 11% of the revenue, customer 3 accounted for

9%, customer 4 account for 4% and customer 5 account for 3%.

----------------------------------
I imagine some shareholders like me  don't know why the priority is on Europe first -- Hopefully Mr Chan knows what is best


<< Previous
Bullboard Posts
Next >>